Literature DB >> 24966942

Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia.

Na Chen1, Kang Lu1, Peipei Li1, Xiao Lv1, Xin Wang2.   

Abstract

Chronic lymphocytic leukemia (CLL) is a common leukemia in adults, but its pathogenesis is still poorly understood. Recently, extensive evidence suggests that the malignant cells of CLL patients secrete a range of cytoprotective cytokines including interleukin-4 (IL-4). IL-4 induced the rapid phosphorylation(p) and activation of the signal transducer and activator of transcription (STAT)-6 transcription factor in CLL cells in vitro. Interleukin-9 (IL-9) is not expressed by Th2 and Th9 cells in the absence of STAT6 expression. To elucidate whether there was a function link between IL-9 and STAT6 in CLL, MEC-1 cells were analyzed using RT-PCR, and western blot. Interestingly, when added with recombinant human IL-4 (rIL-4) in culturing MEC-1 cells, expressions of p-STAT6 and IL-9 in MEC-1 cells increased at a time-dependent manner and their expressions could be inhibited by STAT6 inhibitor. Our data indicated that the upregulation of IL-9 induced by pSTAT6 may be involved in the pathogenesis of CLL.

Entities:  

Keywords:  chronic lymphocytic leukemia; pSTAT6; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24966942      PMCID: PMC4069881     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  28 in total

1.  Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia.

Authors:  Francesca Zonta; Mario Angelo Pagano; Livio Trentin; Elena Tibaldi; Federica Frezzato; Cristina Gattazzo; Veronica Martini; Valentina Trimarco; Marco Mazzorana; Luciana Bordin; Gianpietro Semenzato; Anna Maria Brunati
Journal:  Blood       Date:  2013-12-18       Impact factor: 22.113

2.  Morphology and expression status investigations of specific surface markers on B-cell chronic lymphocytic leukemia cells.

Authors:  Suli Niu; Ryan Chan; Pierre Berini; Chen Wang; Shan Zou
Journal:  Microsc Res Tech       Date:  2013-08-20       Impact factor: 2.769

Review 3.  Innate lymphoid cells: new paradigm in immunology of inflammation.

Authors:  Vijay Kumar
Journal:  Immunol Lett       Date:  2013-11-11       Impact factor: 3.685

4.  STAT6 polymorphisms are associated with neonatal regulatory T cells and cytokines and atopic diseases at 3 years.

Authors:  V I Casaca; S Illi; E Klucker; N Ballenberger; M Schedel; E von Mutius; M Kabesch; B Schaub
Journal:  Allergy       Date:  2013-09-21       Impact factor: 13.146

Review 5.  From interleukin-9 to T helper 9 cells.

Authors:  Michael Stassen; Edgar Schmitt; Tobias Bopp
Journal:  Ann N Y Acad Sci       Date:  2012-01-11       Impact factor: 5.691

6.  CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.

Authors:  Wei Ju; Meili Zhang; Jian-kang Jiang; Craig J Thomas; Unsong Oh; Bonita R Bryant; Jing Chen; Noriko Sato; Yutaka Tagaya; John C Morris; John E Janik; Steven Jacobson; Thomas A Waldmann
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

7.  HLA-G expression as a prognostic indicator in B-cell chronic lymphocytic leukemia.

Authors:  Mohamed A Attia; Nahla A Nosair; Amro Gawally; Gamal Elnagar; Eid M Elshafey
Journal:  Acta Haematol       Date:  2014-02-15       Impact factor: 2.195

8.  Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.

Authors:  Tekla Hornakova; Judith Staerk; Yohan Royer; Elisabetta Flex; Marco Tartaglia; Stefan N Constantinescu; Laurent Knoops; Jean-Christophe Renauld
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

9.  Lymphomagenesis, hydronephrosis, and autoantibodies result from dysregulation of IL-9 and are differentially dependent on Th2 cytokines.

Authors:  Angus J Lauder; Helen E Jolin; Philippa Smith; José G van den Berg; Alison Jones; William Wisden; Kenneth G C Smith; Ayan Dasvarma; Padraic G Fallon; Andrew N J McKenzie
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

10.  Reprogramming of lysosomal gene expression by interleukin-4 and Stat6.

Authors:  Louise M Brignull; Zsolt Czimmerer; Hafida Saidi; Bence Daniel; Izabel Villela; Nathan W Bartlett; Sebastian L Johnston; Lisiane B Meira; Laszlo Nagy; Axel Nohturfft
Journal:  BMC Genomics       Date:  2013-12-05       Impact factor: 3.969

View more
  11 in total

Review 1.  The development and in vivo function of T helper 9 cells.

Authors:  Mark H Kaplan; Matthew M Hufford; Matthew R Olson
Journal:  Nat Rev Immunol       Date:  2015-04-07       Impact factor: 53.106

2.  Human Vδ2 T cells are a major source of interleukin-9.

Authors:  Christian Peters; Robert Häsler; Daniela Wesch; Dieter Kabelitz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

Review 3.  The Role of Interleukin-9 in Cancer.

Authors:  Jacob E Lee; Ziwen Zhu; Qian Bai; Tucker J Brady; Huaping Xiao; Mark R Wakefield; Yujiang Fang
Journal:  Pathol Oncol Res       Date:  2019-04-23       Impact factor: 3.201

4.  STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides.

Authors:  Pablo A Vieyra-Garcia; Tianling Wei; David Gram Naym; Simon Fredholm; Regina Fink-Puches; Lorenzo Cerroni; Niels Odum; John T O'Malley; Robert Gniadecki; Peter Wolf
Journal:  Clin Cancer Res       Date:  2016-02-05       Impact factor: 12.531

5.  Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis.

Authors:  Bangli Hu; Huang Qiu-Lan; Rong-E Lei; Cheng Shi; Hai-Xing Jiang; Shan-Yu Qin
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

6.  Ectopically Expressed Membrane-bound Form of IL-9 Exerts Immune-stimulatory Effect on CT26 Colon Carcinoma Cells.

Authors:  Van Anh Do Thi; Sang Min Park; Hayyoung Lee; Young Sang Kim
Journal:  Immune Netw       Date:  2018-02-22       Impact factor: 6.303

7.  Expression and clinical significance of interleukin-9 in renal tumors.

Authors:  Zhiyu Zhang; Qi Zhou; Jun Ouyang; Jinxian Pu; Jianquan Hou; Jianglei Zhang
Journal:  Transl Androl Urol       Date:  2020-12

8.  TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.

Authors:  Richard E Beatson; Ana C Parente-Pereira; Leena Halim; Domenico Cozzetto; Caroline Hull; Lynsey M Whilding; Olivier Martinez; Chelsea A Taylor; Jana Obajdin; Kim Ngan Luu Hoang; Benjamin Draper; Ayesha Iqbal; Tom Hardiman; Tomasz Zabinski; Francis Man; Rafael T M de Rosales; Jinger Xie; Fred Aswad; Daniela Achkova; Chung-Yang Ricardo Joseph; Sara Ciprut; Antonella Adami; Helge G Roider; Holger Hess-Stumpp; Balázs Győrffy; Jelmar Quist; Anita Grigoriadis; Anette Sommer; Andrew N J Tutt; David M Davies; John Maher
Journal:  Cell Rep Med       Date:  2021-12-21

9.  Antibody-based delivery of interleukin-9 to neovascular structures: Therapeutic evaluation in cancer and arthritis.

Authors:  Baptiste Gouyou; Tiziano Ongaro; Samuele Cazzamalli; Roberto De Luca; Anne Kerschenmeyer; Philippe Valet; Alessandra Villa; Dario Neri; Mattia Matasci
Journal:  Exp Biol Med (Maywood)       Date:  2021-01-21

Review 10.  IL-9 and IL-9-producing cells in tumor immunity.

Authors:  Jie Wan; Yinqiu Wu; Xiaoyun Ji; Lan Huang; Wei Cai; Zhaoliang Su; Shengjun Wang; Huaxi Xu
Journal:  Cell Commun Signal       Date:  2020-03-30       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.